Paternal Exposure to Methotrexate and Pregnancy Outcomes

Journal of Rheumatology - Tập 38 Số 4 - Trang 628-632 - 2011
Delphine Beghin1, Maxime Cournot2,3, Catherine Vauzelle2, Elisabeth Éléfant2,3
1Centre de Référence sur les Agents Tératogènes (CRAT), Hôpital Armand Trousseau, Groupe Universitaire Est, Paris, France.
2From the Centre de Référence sur les Agents Tératogènes (CRAT), Hôpital Armand Trousseau, Groupe Universitaire Est, Paris, France.
3Hôpital Armand Trousseau, Groupe Universitaire Est.

Tóm tắt

Objective.To assess the risk of major malformation in the case of paternal exposure to methotrexate (MTX) at the time of conception.Methods.Using prospective data of our Teratology Information Service, we analyzed outcomes of paternal MTX exposure at the time of conception or up to 3 months before conception.Results.We report on the outcomes of 42 pregnancies involving 40 men treated with MTX at the time of conception. Twenty-three men were treated for an inflammatory disease (54.8%), 9 for psoriasis (21.4%), and 8 for a malignant disease (19.0%). Weekly dosages varied between 7.5 mg and 30 mg. The pregnancies resulted in 36 live births, 3 spontaneous abortions, and 3 voluntary abortions. No congenital malformation was observed at birth.Conclusion.Based on our results and case reports in literature, paternal MTX exposure at the time of conception does not seem to raise any major concern for offspring.

Từ khóa


Tài liệu tham khảo

Reich, 1978, Recognition in adult patients of malformations induced by folic-acid antagonists, Birth Defects Orig Arctic Ser, 14, 139

10.1002/art.1780400527

10.1002/tera.1420460107

EUROCAT . Minor anomalies for exclusion. [Internet. Accessed Nov 22, 2010]. 2005. Available from: http://www.eurocat-network.eu/content/EUROCAT-New-List-of-Minor-Anomalies.pdf

10.1111/j.1572-0241.2006.00867_13.x

10.1002/ibd.20722

Ostensen, 2007, Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease, J Rheumatol, 34, 1266

10.1159/000254035

10.1001/archderm.1983.01650350002002

Weinstein, 1977, Methotrexate, Ann Intern Med, 86, 199, 10.7326/0003-4819-86-2-199

10.3899/jrheum.080554

Matthews, 1980, Male fertility during chemotherapy for acute leukemia, N Engl J Med, 303, 1235, 10.1056/NEJM198011203032113

10.1001/jama.1973.03220130040009

10.1136/bmj.1.6072.1322-a

10.3109/08880018609031234

Riccardi, 1982, Methotrexate levels in the interstitial space and seminiferous tubule of rat testis, Cancer Res, 42, 1617

10.1016/0165-1218(92)90007-M

Melnyk, 1971, Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate, Clin Genet, 2, 28, 10.1111/j.1399-0004.1971.tb00251.x

Jensen, 1979, Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test, Mutat Res, 64, 339, 10.1016/0165-1161(79)90126-2

10.1097/00004032-200307000-00013

10.1086/301677

10.1016/j.fertnstert.2009.05.068

10.1001/archderm.1980.01640260091025

Estop, 1992, Sperm chromosome studies in patients taking low dose methotrexate [abstract], Am J Hum Genet, 51, A314

Thông tin
Thông tin xuất bản

Journal of Rheumatology

Tập 38 Số 4

628-632

Thông tin tác giả